Alembic receives USFDA final approval for Paroxetine Extended-Release Tablets
Paroxetine extended-release tablets are indicated for the treatment of major depressive disorder
Paroxetine extended-release tablets are indicated for the treatment of major depressive disorder
Pregabalin Capsules have an estimated market size of US $244 million for twelve months ending Sep 2022 according to IQVIA
Subscribe To Our Newsletter & Stay Updated